Biostate AI Expands Global Reach with Strategic Partnerships in US, China, and India

Biostate AI, a biotechnology company specializing in RNA sequencing and artificial intelligence for precision medicine, has announced the establishment of strategic research partnerships spanning three continents. The company has secured collaborations with Mass General Brigham in the United States, formed a joint venture with China's Kindstar Global Gene Technology, and launched an Indian subsidiary called Bayosthiti.

Biostate AI develops AI models using RNA sequencing data to predict disease evolution and guide treatment decisions. The company's proprietary BIRT (Barcode-Integrated Reverse Transcription) technology enables cost-effective, large-scale RNA sequencing analysis.

Founded in 2023 by David Zhang (former Rice University professor) and Ashwin Gopinath (former MIT professor), Biostate AI raised $12 million in Series A funding led by Accel in May 2025. The company has developed over 12 patented technologies and collaborates with more than 100 research institutions across the United States.

Strategic Partnerships

United States: Mass General Brigham Collaboration

Biostate AI is partnering with Mass General Brigham to develop AI models for melanoma immunotherapy, specifically targeting immune checkpoint inhibitor treatments. The collaboration aims to improve the safety and effectiveness of these expensive therapies, which currently have inconsistent response rates and risk of severe side effects.

"Our group has assembled thousands of paired tumor and blood specimens linked to detailed longitudinal outcomes," stated Dr. Genevieve Boland, Section Head of Melanoma/Sarcoma Surgery at Massachusetts General Hospital. "This collaboration allows us to leverage AI in new ways to unlock that data, which can better inform patient care in the future."

The partnership plans to utilize Mass General Brigham's melanoma tumor biobank to create diagnostic models with potential applications beyond melanoma to other cancers treated with checkpoint inhibitors.

China: Kindstar Global Joint Venture

Biostate AI has formed a joint venture with Kindstar Global Gene Technology, a clinical diagnostics company listed on the Hong Kong Stock Exchange (9960.HK). The collaboration will adapt Biostate AI's RNA sequencing and AI platform for the Chinese population, focusing on five high-prevalence medical areas:

• Autoimmune diseases
• Oral cancer
• Diabetes
• Lymphoma
• Post-transplant care

Kindstar Global operates a network covering over 3,000 healthcare institutions in China, including more than 90% of top-tier hospitals.

David Zhang, Co-founder and CEO of Biostate AI, commented: "We're thrilled to partner with Kindstar Global. As a leading specialty testing provider in China, their national clinical network of over 3,000 hospitals and deep market resources make them an ideal partner."

India: Bayosthiti Subsidiary Launch

Biostate AI has established Bayosthiti, an Indian subsidiary focused on developing precision cancer diagnostics tailored to the Indian population. The subsidiary will collaborate with hospital systems and cancer centers to address India's growing cancer challenge, with over 1.4 million new cases diagnosed annually.

"Our technologies have been validated through collaborations with over 100 academic and biotech partners in the U.S., and now we're applying these proven capabilities to India's unique healthcare setting," explained Ashwin Gopinath, Co-founder and CTO of Biostate AI. "Our confluence of advanced AI models and wet chemistry innovations gives us both a data advantage and the ability to generate insights that were previously impossible."

Biostate AI addresses critical challenges in precision medicine by recognizing that while diseases like cancer affect populations globally, their biological manifestations and optimal treatments vary by geographic region and population genetics. The company's approach combines:

• Cost reduction: BIRT technology significantly lowers RNA sequencing costs
• Standardization: Unified workflows eliminate batch effects that compromise multi-site studies
• Scale: Ability to process millions of samples to train sophisticated AI models
• Localization: Population-specific diagnostic development

The company has recently appointed Prasad Chintamaneni as an independent board member. Chintamaneni previously served as President of Global Industries and Consulting for Cognizant and as Managing Director at New Mountain Capital, where he currently serves as Senior Advisor.